Mercedes Romero
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1902517915
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations.
Across 202 payments — averaging $29.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$602
- Dexcom, Inc.$572
- Lilly USA, LLC$538
- Bayer$455
- Corcept Therapeutics$371
- Cequr Corporation$338
- plus $3K from 27 others
What the payments were for
- Food & beverage$5,858100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 18 | $602 |
| Dexcom, Inc. | 17 | $572 |
| Lilly USA, LLC | 30 | $538 |
| Bayer | 16 | $455 |
| Corcept Therapeutics | 7 | $371 |
| Cequr Corporation | 1 | $338 |
| Tandem Diabetes Care, Inc. | 9 | $313 |
| Insulet Corporation | 8 | $312 |
| Mannkind Corporation | 5 | $218 |
| Medtronic | 5 | $206 |
| Novo Nordisk | 10 | $201 |
| Radius Health, Inc. | 8 | $173 |
| Ascendis Pharma Endocrinology Inc | 7 | $169 |
| Sequel Med Tech, LLC | 2 | $167 |
| Sanofi-aventis U.S. LLC | 7 | $163 |
| Amgen | 7 | $129 |
| Recordati_rare_diseases_inc. | 6 | $118 |
| Chiesi USA, Inc. | 4 | $101 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| AbbVie | 5 | $89 |
| Madrigal Pharmaceuticals | 3 | $83 |
| Novartis | 3 | $83 |
| Amphastar Pharmaceuticals, Inc. | 4 | $67 |
| Amneal Pharmaceuticals LLC | 3 | $57 |
| Averitas Pharma Inc. | 2 | $46 |
| Verity Pharmaceuticals Inc. | 2 | $42 |
| Almatica Pharma LLC | 2 | $41 |
| Soleno Therapeutics, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$338
- Korlym$279
- FREESTYLE LIBRE 3$250
- Kerendia$241
- TWIIST$147
- MINIMED 780G$134
- AFREZZA$132
- DEXCOM G6 TRANSMITTER$119
- Omnipod$114
- t:slim X2 Insulin Pump with Control-IQ$104
How this compares
$5,858 in reported general payments places this provider in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $137,431 |
| MounjaroTirzepatide | 56 | $91,760 |
| JardianceEmpagliflozin | 25 | $39,973 |
| SynthroidLevothyroxine Sodium | 67 | $6,053 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 24 | $2,984 |
| Levothyroxine Sodium | 177 | $1,713 |
| Metformin Hcl ErMetformin Hcl | 50 | $546 |
| Liothyronine Sodium | 14 | $422 |
| Methimazole | 30 | $312 |
| Rosuvastatin Calcium | 18 | $258 |
| Metformin Hcl | 25 | $234 |
| Glimepiride | 25 | $189 |
| Alendronate Sodium | 14 | $175 |
| Atorvastatin Calcium | 11 | $146 |
| Lisinopril | 12 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $201 | $137,43176 claims |
| Lilly USA, LLCMounjaro | $538 | $91,76056 claims |
| Boehringer IngelheimJardiance | $21 | $39,97325 claims |
| AbbVieSynthroid | $89 | $6,05367 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $57 | $1,774189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Amir HarariScottsdale$361K
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$132K
- Sreedevi ReddyScottsdale$28K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Chandana MishraScottsdale$11K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
- Dena HaddadScottsdale$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.